0001558370-23-001226.txt : 20230214 0001558370-23-001226.hdr.sgml : 20230214 20230214074613 ACCESSION NUMBER: 0001558370-23-001226 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230214 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14778 FILM NUMBER: 23622555 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 8-K 1 tmb-20230214x8k.htm 8-K
0000812796falseDE00008127962023-02-142023-02-14

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):  February 14, 2023

 

Commission File No. 001-14778

 

Soligenix, Inc.

(Exact name of small business issuer as specified in its charter)

 

DELAWARE

 

41-1505029

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification Number)

 

 

 

29 Emmons Drive,

Suite B-10

Princeton, NJ

 

08540

(Address of principal executive offices)

 

(Zip Code)

​

(609) 538-8200

(Issuer’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $.001 per share

 

SNGX

 

The Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

w

​

​

​

Item 8.01. Other Events.

​

On February 14, 2022, Soligenix, Inc. (the “Company”) issued a press release announcing that the United States (“U.S.”) Food and Drug Administration provided the Company with a Refusal to File letter for its HyBryte™ (synthetic hypericin) new drug application in the treatment of early stage cutaneous T-cell lymphoma, a rare cancer and area of unmet medical need affecting over 25,000 patients in the U.S.  A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

​

Safe Harbor for Forward-Looking Statements

​

Certain statements contained in this report may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the 1934 Act. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “predicts,” “plans,” “expects,” “anticipates,” “believes,” “goal,” “target,” “estimate,” “potential,” “may,” “might,” “could,” “see,” “seek,” “forecast,” and similar words. Forward-looking statements are based on the Company’s current plans and expectations and involve risks and uncertainties which are, in many instances, beyond the Company’s control, and which could cause actual results to differ materially from those included in or contemplated or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks, uncertainties and factors detailed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including in the Company’s Annual Report for the year ended December 31, 2021 on Form 10-K, which was filed with the SEC. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this report as of the date hereof and assumes no obligations to update the information included in this report or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

​

​

Item 9.01. Financial Statements and Exhibits.

​

(d)     Exhibits.

Exhibit No.

    

Description

99.1

 

Press Release dated February 14, 2023.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

​

​

​

2

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

 

Soligenix, Inc. 

​

​

February 14, 2023 

By:

/s/ Christopher J. Schaber 

 

 

Christopher J. Schaber, Ph.D.

​

​

President and Chief Executive Officer

​

​

(Principal Executive Officer)

​

​

​

3

 EX-99.1 2 tmb-20230214xex99d1.htm EX-99.1

EXHIBIT 99.1

​

soligenixLOWRES

Graphic

​

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval

​

Princeton, NJ – February 14, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (U.S.) Food and Drug Administration (FDA) has provided the Company with a Refusal to File (RTF) letter for its HyBryte™ (synthetic hypericin) new drug application (NDA) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer and area of unmet medical need affecting over 25,000 patients in the U.S.  

​

Upon preliminary review, the FDA determined that the NDA, submitted on December 14, 2022, was not sufficiently complete to permit substantive review. Soligenix first learned of the RTF decision via this letter and is reviewing its contents to determine the appropriate next steps, which includes, but is not limited to, requesting a Type A meeting with the FDA to clarify and respond to the issues identified in the letter and to seek additional guidance concerning information that the agency would require for a resubmitted NDA to be deemed acceptable to file.

“We are fully determined to work with the FDA staff as quickly as possible to better understand the open issues and clarify the potential path to successfully resubmitting our application,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “We remain focused on advancing HyBryte™ as a potential new first-in-class treatment option for the CTCL community of patients, families and healthcare professionals.”

About HyBryte™

HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation.  The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells,

and then activated by visible light approximately 24 hours later.  The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure.  Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients.  In a published Phase 2 clinical study in CTCL, patients experienced a statistically significant (p=0.04) improvement with topical hypericin treatment whereas the placebo was ineffective.  HyBryte™ has received orphan drug and fast track designations from the FDA, as well as orphan designation from the European Medicines Agency (EMA).

The recently published Phase 3 FLASH trial enrolled a total of 169 patients (166 evaluable) with Stage IA, IB or IIA CTCL. The trial consisted of three treatment cycles. Treatments were administered twice weekly for the first 6 weeks and treatment response was determined at the end of the 8th week of each cycle. In the first double-blind treatment cycle, 116 patients received HyBryte™ treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions. A total of 16% of the patients receiving HyBryte™ achieved at least a 50% reduction in their lesions (graded using a standard measurement of dermatologic lesions, the CAILS score) compared to only 4% of patients in the placebo group at 8 weeks (p=0.04) during the first treatment cycle (primary endpoint). HyBryte™ treatment in the first cycle was safe and well tolerated.

In the second open-label treatment cycle (Cycle 2), all patients received HyBryte™ treatment of their index lesions. Evaluation of 155 patients in this cycle (110 receiving 12 weeks of HyBryte™ treatment and 45 receiving 6 weeks of placebo treatment followed by 6 weeks of HyBryte™ treatment), demonstrated that the response rate among the 12-week treatment group was 40% (p<0.0001 vs the placebo treatment rate in Cycle 1). Comparison of the 12-week and 6-week treatment groups also revealed a statistically significant improvement (p<0.0001) between the two groups, indicating that continued treatment results in better outcomes.  HyBryte™ continued to be safe and well tolerated. Additional analyses also indicated that HyBryte™ is equally effective in treating both plaque (response 42%, p<0.0001 relative to placebo treatment in Cycle 1) and patch (response 37%, p=0.0009 relative to placebo treatment in Cycle 1) lesions of CTCL, a particularly relevant finding given the historical difficulty in treating plaque lesions in particular.

The third (optional) treatment cycle (Cycle 3) was focused on safety and all patients could elect to receive HyBryte™ treatment of all their lesions. Of note, 66% of patients elected to continue with this optional compassionate use / safety cycle of the study. Of the subset of patients that received HyBryte™ throughout all 3 cycles of treatment, 49% of them demonstrated a positive treatment response (p<0.0001 vs patients receiving placebo in Cycle 1). Moreover, in a subset of patients evaluated in this cycle, it was demonstrated that HyBryte™ is not systemically available, consistent with the general safety of this topical product observed to date. At the end of Cycle 3, HyBryte™ continued to be well tolerated despite extended and increased use of the product to treat multiple lesions.

Overall safety of HyBryte™ is a critical attribute of this treatment and was monitored throughout the three treatment cycles (Cycles 1, 2 and 3) and the 6-month follow-up period.  HyBryte's™

2

​

mechanism of action is not associated with DNA damage, making it a safer alternative than currently available therapies, all of which are associated with significant and sometimes fatal, side effects.  Predominantly these include the risk of melanoma and other malignancies, as well as the risk of significant skin damage and premature skin aging.  Currently available treatments are only approved in the context of previous treatment failure with other modalities and there is no approved front-line therapy available.  Within this landscape, treatment of CTCL is strongly motivated by the safety risk of each product.  HyBryte™ potentially represents the safest available efficacious treatment for CTCL.  With very limited systemic absorption, a compound that is not mutagenic and a light source that is not carcinogenic, there is no evidence to date of any potential safety issues. 

The Phase 3 CTCL clinical study was partially funded by the National Cancer Institute via a Phase II SBIR grant (#1R44CA210848-01A1) awarded to Soligenix, Inc.  In addition, the FDA awarded an Orphan Products Development grant to support the evaluation of HyBryte™ for expanded treatment in patients with early-stage CTCL, including in the home use setting.  The grant, totaling $2.6 million over 4 years, was awarded to a prestigious academic institution that was a leading enroller in the Phase 3 FLASH study.

About Cutaneous T-Cell Lymphoma (CTCL)

​

CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system.  Unlike most NHLs which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell lymphocytes (involved in cell-mediated immunity) normally programmed to migrate to the skin.  These malignant cells migrate to the skin where they form various lesions, typically beginning as patches and may progress to raised plaques and tumors.  Mortality is related to the stage of CTCL, with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced. There is currently no cure for CTCL.  Typically, CTCL lesions are treated and regress but usually return either in the same part of the body or in new areas.

​

CTCL constitutes a rare group of NHLs, occurring in about 4% of the approximate 700,000 individuals living with the disease.  It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of CTCL that it affects over 25,000 individuals in the U.S., with approximately 3,000 new cases seen annually.

About Soligenix, Inc.

​

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary

3

​

formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).

​

Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.

This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the FDA’s acceptance of the NDA for HyBryte™, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 1/2 proof-of-concept clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. HyBryte™ potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this information. While the Company has determined this potential market size based on assumptions that its believes are reasonable, there are a number of factors that could cause expectations to change or not be realized.  These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

​

4

​

Company Contact:

​

Jonathan Guarino, CPA, CGMA

Senior Vice President and Chief Financial Officer

(609) 538-8200 | www.soligenix.com

Soligenix, Inc.

29 Emmons Drive, Suite B-10

Princeton, NJ 08540

5

​

 GRAPHIC 3 tmb-20230214xex99d1001.jpg GRAPHIC begin 644 tmb-20230214xex99d1001.jpg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end GRAPHIC 4 tmb-20230214xex99d1002.jpg GRAPHIC begin 644 tmb-20230214xex99d1002.jpg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end EX-101.SCH 5 tmb-20230214.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 tmb-20230214_def.xml EX-101.DEF EX-101.LAB 7 tmb-20230214_lab.xml EX-101.LAB EX-101.PRE 8 tmb-20230214_pre.xml EX-101.PRE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Feb. 14, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 14, 2023
Securities Act File Number 001-14778
Entity Registrant Name Soligenix, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 41-1505029
Entity Address, Address Line One 29 Emmons Drive
Entity Address, Address Line Two Suite B-10
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 609
Local Phone Number 538-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.001 per share
Trading Symbol SNGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000812796
Amendment Flag false
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.22.4
N-2
Feb. 14, 2023
Cover [Abstract]  
Entity Central Index Key 0000812796
Amendment Flag false
Securities Act File Number 001-14778
Document Type 8-K
Entity Registrant Name Soligenix, Inc.
Entity Address, Address Line One 29 Emmons Drive
Entity Address, Address Line Two Suite B-10
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 609
Local Phone Number 538-8200
Entity Emerging Growth Company false
XML 11 tmb-20230214x8k_htm.xml IDEA: XBRL DOCUMENT 0000812796 2023-02-14 2023-02-14 0000812796 false DE 8-K 2023-02-14 001-14778 Soligenix, Inc. 41-1505029 29 Emmons Drive Suite B-10 Princeton NJ 08540 609 538-8200 false false false false Common Stock, par value $.001 per share SNGX NASDAQ false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,8]3E8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #&/4Y6 D/.S^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$E*!R;-9:6G#08K;.QF;+4UB_]@:R1]^R5>FS*V!]C1TL^? M/H%:%83R$9^C#QC)8+H;;>^24&'#3D1! "1U0BM3.27+3I*4)45L&Z> M&,YCW\(-,,,(HTW?!=0+,5?_Q.8.L$MR3&9)#<-0#DW.33M4\/;T^)+7+8Q+ M))W"Z5&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #&/4Y6^#R.$&L$ W$0 & 'AL+W=OP'-V9)/D@-\ M^ZX,L;D[LZ3-B_A1?_^\N_JO3'^M]">S K!LDZ72#+R5M?FU[YMX!1DW%RH' MB5<62F?^B;7P)-R4);Z41!T_(P+Z0W[Y;F)'O9585,A8:*9*;*,Z^T- MI&H]\$+OY<236*ZL.^$/^SE?PA3L[_E$XY%?J20B VF$DDS#8N"-PNN;J.T& ME'?\(6!M#O:9>Y6Y4I_7V;.#8Q5^E$D=C7P>AY+8,&+U#ZI]2^P?Z$2,%:I*?^S]>[>5LMC M<6&LRO:#D2 36BE*GVG\M>NT-JDX!3B0@LKP+!1;-F]2($]%MD< M=!,GXNJ06OM:?X*E<)6%L7OD66/ :)VI2L42I-B$82]BK#W&L(9 MW["'!,M.+$1<8A*9I15;F-AVT ZB*P+OJL*[>@W>*$EPNINSEQWV#N]C'V1C MU&C%Z(K=99F2AMUJ;"($8QC4QAO\?\K96C5:+RTY+036R,UY&%"$!ZTA_$^$ M8W>$%3A3Z^;&0,M-M) QV*^;RI=P=5L(25?_!JZ:'Q.MGMV#&@EIS<=?*;2Z M(X2TIW^--E'&\I3])?*CD_:$8M!KM\B]4C#&9K)2D^L$)D?9E[[R'"U"*J&X((>WD'[%-69 8F"PKY-[13",5 M+;3@J2$]HNX$(>W6KKG$V#SEDKW'\M:"IXT\M,I)GMKW0]JF)QK.8PP/X/S: M+7I )K@\^[!8',D?K7>2K+;\D';H;\@>C"F0["0@+7L*,*KM/J*]>28LKGS4 M@H71C_.?V'Y9M&U>*J;[K-YJJQ]DX(3!_?_$F1''P&T-[\$C!VMXE77"[AZ'KMA-#C M:'H[^HUBJHT^>I71WV6@ERY*;U#!KIR!Y%PVIY86/%ENM<]'M$WOT<8X%33Z M[ /.@@U["\U0M%2 ?[TPZEYU*++:^"/:LTXK?7=@55Y^&<^5Q>_L*/PY#1L.T'9XZN M=EK,S>5F5*_7'"9#KS $4$&B746'"_W,(8LKS-ZJ]0?83J@$3%1F MRE^VWO1MMCR6K(Q5^5:,!+F0FRM_V"[$GB#L'!!$6T%4#@-Z'OPAF_?A)W@'<'7K/B:E/OP7%IA']D8)/)E[%*F\,"NX+&.DW8*\!.' M4;?7(;!:%5:+-!OAVY'BU[*+C"_J8&C]G&<&"(YVQ=$F?::0K+2P @P;)0@C M,F WJWP&NHZ)]@J"L!&VNMV8X.I47!W2ZTPEJW)Y[AX+J$.AY7'CBH#H5A#= MEYR=6U@(=[J1YH;GM32TSU1E8@%2/!SA^4N.";*X(HM?0C9*4WQCS-%3@UUC M/_99UC+2CE&/G>>YDH:=:O@IM:CG-'NHE6]VZ@6D+:\^8C MA;;+^"&9L/]!FRAC,;5^%P4;J[0>C'8,XG:+W--=M@_I)%WNX0AKG,,HM$$G MZ%$@N_P>T@GZ6B6X)I.EDE1"?<:DW8P;,19I%-$NTX=T>MYNVWD.>B'D@KU' M![O$=CX+B+OGI3&PO9KEMWDOSAR+DC MO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-B MK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@ MI+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTP MY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36 M-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO M<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#V MG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ M+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /, M)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AME ML,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>> MQ[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( M ,8]3E:7BKL

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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.soligenix.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995470 - Disclosure - N-2 Sheet http://xbrl.sec.gov/cef/role/N2 N-2 Notes 2 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode - tmb-20230214x8k.htm 9 tmb-20230214x8k.htm tmb-20230214.xsd tmb-20230214_def.xml tmb-20230214_lab.xml tmb-20230214_pre.xml tmb-20230214xex99d1.htm http://xbrl.sec.gov/dei/2022 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tmb-20230214x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "tmb-20230214_def.xml" ] }, "inline": { "local": [ "tmb-20230214x8k.htm" ] }, "labelLink": { "local": [ "tmb-20230214_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20230214_pre.xml" ] }, "schema": { "local": [ "tmb-20230214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldi-2006.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/cef/2022/cef-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022_lab.xsd" ] } }, "elementCount": 199, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sngx", "nsuri": "http://www.soligenix.com/20230214", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20230214x8k.htm", "contextRef": "Duration_2_14_2023_To_2_14_2023_Oj1OzHkiakGn5gZF-aSsgg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20230214x8k.htm", "contextRef": "Duration_2_14_2023_To_2_14_2023_Oj1OzHkiakGn5gZF-aSsgg", "decimals": null, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "tmb-20230214x8k.htm", "contextRef": "Duration_2_14_2023_To_2_14_2023_Oj1OzHkiakGn5gZF-aSsgg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityFileNumber", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995470 - Disclosure - N-2", "menuCat": "Notes", "order": "2", "role": "http://xbrl.sec.gov/cef/role/N2", "shortName": "N-2", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 0, "tag": { "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundFeesAndExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "localname": "AcquiredFundFeesAndExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AllRisksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Risks:" } } }, "localname": "AllRisksMember", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "cef_AllSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Securities:" } } }, "localname": "AllSecuritiesMember", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "cef_AnnualCoverageReturnRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]" } } }, "localname": "AnnualCoverageReturnRatePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualDividendPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment" } } }, "localname": "AnnualDividendPayment", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualDividendPaymentCurrent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current" } } }, "localname": "AnnualDividendPaymentCurrent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualDividendPaymentInitial": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial" } } }, "localname": "AnnualDividendPaymentInitial", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]" } } }, "localname": "AnnualExpensesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AnnualInterestRateCurrentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]" } } }, "localname": "AnnualInterestRateCurrentPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualInterestRateInitialPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]" } } }, "localname": "AnnualInterestRateInitialPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualInterestRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]" } } }, "localname": "AnnualInterestRatePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_BasisOfTransactionFeesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Transaction Fees, Note [Text Block]" } } }, "localname": "BasisOfTransactionFeesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_BdcFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BDC File Number" } } }, "localname": "BdcFileNumber", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "cef_BusinessDevelopmentCompanyFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Development Company [Flag]" } } }, "localname": "BusinessDevelopmentCompanyFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } }, "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_CapitalStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock [Table Text Block]" } } }, "localname": "CapitalStockTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_DistributionServicingFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "localname": "DistributionServicingFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DistributionsMayReducePrincipalTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "localname": "DistributionsMayReducePrincipalTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_DividendAndInterestExpensesOnShortSalesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "localname": "DividendAndInterestExpensesOnShortSalesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DividendExpenseOnPreferredSharesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "localname": "DividendExpenseOnPreferredSharesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DividendReinvestmentAndCashPurchaseFees": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend Reinvestment and Cash Purchase Fees" } } }, "localname": "DividendReinvestmentAndCashPurchaseFees", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_EffectsOfLeveragePurposeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage, Purpose [Text Block]" } } }, "localname": "EffectsOfLeveragePurposeTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_EffectsOfLeverageTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Table Text Block]" } } }, "localname": "EffectsOfLeverageTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_EffectsOfLeverageTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Text Block]" } } }, "localname": "EffectsOfLeverageTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ExpenseExampleTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example [Table Text Block]" } } }, "localname": "ExpenseExampleTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ExpenseExampleYear01": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Year 01" } } }, "localname": "ExpenseExampleYear01", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to10": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 10" } } }, "localname": "ExpenseExampleYears1to10", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 3" } } }, "localname": "ExpenseExampleYears1to3", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to5": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 5" } } }, "localname": "ExpenseExampleYears1to5", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_FeeTableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fee Table [Abstract]" } } }, "localname": "FeeTableAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_FinancialHighlightsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Highlights [Abstract]" } } }, "localname": "FinancialHighlightsAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_GeneralDescriptionOfRegistrantAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "localname": "GeneralDescriptionOfRegistrantAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_HighestPriceOrBid": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid" } } }, "localname": "HighestPriceOrBid", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_HighestPriceOrBidNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, NAV" } } }, "localname": "HighestPriceOrBidNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_HighestPriceOrBidPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationMaximumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation Maximum [Percent]" } } }, "localname": "IncentiveAllocationMaximumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationMinimumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation Minimum [Percent]" } } }, "localname": "IncentiveAllocationMinimumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation [Percent]" } } }, "localname": "IncentiveAllocationPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Fees [Percent]" } } }, "localname": "IncentiveFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_InterestExpensesOnBorrowingsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "localname": "InterestExpensesOnBorrowingsPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IntervalFundFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interval Fund [Flag]" } } }, "localname": "IntervalFundFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_InvestmentObjectivesAndPracticesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Objectives and Practices [Text Block]" } } }, "localname": "InvestmentObjectivesAndPracticesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LatestNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest NAV" } } }, "localname": "LatestNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LatestPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest Premium (Discount) to NAV [Percent]" } } }, "localname": "LatestPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_LatestSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest Share Price" } } }, "localname": "LatestSharePrice", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LoanServicingFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Servicing Fees [Percent]" } } }, "localname": "LoanServicingFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_LongTermDebtDividendsAndCovenantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Dividends and Covenants [Text Block]" } } }, "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Issuance and Substitution [Text Block]" } } }, "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Principal" } } }, "localname": "LongTermDebtPrincipal", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]" } } }, "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtStructuringTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Structuring [Text Block]" } } }, "localname": "LongTermDebtStructuringTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt [Table Text Block]" } } }, "localname": "LongTermDebtTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Title [Text Block]" } } }, "localname": "LongTermDebtTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LowestPriceOrBid": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid" } } }, "localname": "LowestPriceOrBid", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LowestPriceOrBidNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, NAV" } } }, "localname": "LowestPriceOrBidNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LowestPriceOrBidPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Fee not based on Net Assets, Note [Text Block]" } } }, "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ManagementFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Fees [Percent]" } } }, "localname": "ManagementFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_NetExpenseOverAssetsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Expense over Assets [Percent]" } } }, "localname": "NetExpenseOverAssetsPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_NewCefOrBdcRegistrantFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New CEF or BDC Registrant [Flag]" } } }, "localname": "NewCefOrBdcRegistrantFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_NoPublicTradingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No Public Trading [Text Block]" } } }, "localname": "NoPublicTradingTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_NoTradingHistoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No Trading History [Text Block]" } } }, "localname": "NoTradingHistoryTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherAnnualExpense1Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 1.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 1 [Percent]" } } }, "localname": "OtherAnnualExpense1Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpense2Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 2.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 2 [Percent]" } } }, "localname": "OtherAnnualExpense2Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpense3Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 3.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 3 [Percent]" } } }, "localname": "OtherAnnualExpense3Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Abstract]" } } }, "localname": "OtherAnnualExpensesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_OtherAnnualExpensesPercent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Percent]" } } }, "localname": "OtherAnnualExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Expenses, Note [Text Block]" } } }, "localname": "OtherExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherFeederFundExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Feeder Fund Expenses [Percent]" } } }, "localname": "OtherFeederFundExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherMasterFundExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Master Fund Expenses [Percent]" } } }, "localname": "OtherMasterFundExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Securities [Table Text Block]" } } }, "localname": "OtherSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherSecurityDescriptionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Security, Description [Text Block]" } } }, "localname": "OtherSecurityDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherSecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Security, Title [Text Block]" } } }, "localname": "OtherSecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherTransactionExpense1Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 1.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 1 [Percent]" } } }, "localname": "OtherTransactionExpense1Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpense2Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 2.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 2 [Percent]" } } }, "localname": "OtherTransactionExpense2Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpense3Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 3.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 3 [Percent]" } } }, "localname": "OtherTransactionExpense3Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Abstract]" } } }, "localname": "OtherTransactionExpensesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_OtherTransactionExpensesPercent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Percent]" } } }, "localname": "OtherTransactionExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionFeesBasisMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum" } } }, "localname": "OtherTransactionFeesBasisMaximum", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_OtherTransactionFeesBasisMaximumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum [Percent]" } } }, "localname": "OtherTransactionFeesBasisMaximumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionFeesBasisNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Note [Text Block]" } } }, "localname": "OtherTransactionFeesBasisNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherTransactionFeesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees, Note [Text Block]" } } }, "localname": "OtherTransactionFeesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OutstandingSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Securities [Table Text Block]" } } }, "localname": "OutstandingSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OutstandingSecurityAuthorizedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Authorized [Shares]" } } }, "localname": "OutstandingSecurityAuthorizedShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityHeldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Held [Shares]" } } }, "localname": "OutstandingSecurityHeldShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityNotHeldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Not Held [Shares]" } } }, "localname": "OutstandingSecurityNotHeldShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Title [Text Block]" } } }, "localname": "OutstandingSecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PreferredStockRestrictionsArrearageTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]" } } }, "localname": "PreferredStockRestrictionsArrearageTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PreferredStockRestrictionsOtherTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]" } } }, "localname": "PreferredStockRestrictionsOtherTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PrimaryShelfFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Primary Shelf [Flag]" } } }, "localname": "PrimaryShelfFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_PrimaryShelfQualifiedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]" } } }, "localname": "PrimaryShelfQualifiedFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_ProspectusLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]" } } }, "localname": "ProspectusLineItems", "nsuri": "http://xbrl.sec.gov/cef/2022", "xbrltype": "stringItemType" }, "cef_ProspectusTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prospectus:" } } }, "localname": "ProspectusTable", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_PurposeOfFeeTableNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purpose of Fee Table , Note [Text Block]" } } }, "localname": "PurposeOfFeeTableNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RegisteredClosedEndFundFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Registered Closed-End Fund [Flag]" } } }, "localname": "RegisteredClosedEndFundFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_ReturnAtMinusFivePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Minus Five [Percent]" } } }, "localname": "ReturnAtMinusFivePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtMinusTenPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Minus Ten [Percent]" } } }, "localname": "ReturnAtMinusTenPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtPlusFivePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Plus Five [Percent]" } } }, "localname": "ReturnAtPlusFivePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtPlusTenPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Plus Ten [Percent]" } } }, "localname": "ReturnAtPlusTenPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtZeroPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Zero [Percent]" } } }, "localname": "ReturnAtZeroPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_RightsLimitedByOtherSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Limited by Other Securities [Text Block]" } } }, "localname": "RightsLimitedByOtherSecuritiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Subject to Other than Majority Vote [Text Block]" } } }, "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RiskAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk [Axis]" } } }, "localname": "RiskAxis", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_RiskFactorsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk Factors [Table Text Block]" } } }, "localname": "RiskFactorsTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RiskTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk [Text Block]" } } }, "localname": "RiskTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SalesLoadPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales Load [Percent]" } } }, "localname": "SalesLoadPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_SecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security [Axis]" } } }, "localname": "SecurityAxis", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_SecurityDividendsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Dividends [Text Block]" } } }, "localname": "SecurityDividendsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Liabilities [Text Block]" } } }, "localname": "SecurityLiabilitiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityLiquidationRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Liquidation Rights [Text Block]" } } }, "localname": "SecurityLiquidationRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityObligationsOfOwnershipTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Obligations of Ownership [Text Block]" } } }, "localname": "SecurityObligationsOfOwnershipTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityPreemptiveAndOtherRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Preemptive and Other Rights [Text Block]" } } }, "localname": "SecurityPreemptiveAndOtherRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Title [Text Block]" } } }, "localname": "SecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityVotingRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Voting Rights [Text Block]" } } }, "localname": "SecurityVotingRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Amount" } } }, "localname": "SeniorSecuritiesAmount", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_SeniorSecuritiesAverageMarketValuePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Average Market Value per Unit" } } }, "localname": "SeniorSecuritiesAverageMarketValuePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Averaging Method, Note [Text Block]" } } }, "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesCoveragePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit" } } }, "localname": "SeniorSecuritiesCoveragePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesHeadingsNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Headings, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHeadingsNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Annualized, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Audited, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Involuntary Liquidating Preference per Unit" } } }, "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities, Note [Text Block]" } } }, "localname": "SeniorSecuritiesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities [Table Text Block]" } } }, "localname": "SeniorSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SharePriceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Price [Table Text Block]" } } }, "localname": "SharePriceTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SharePricesNotActualTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Prices Not Actual Transactions [Text Block]" } } }, "localname": "SharePricesNotActualTransactionsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ShareholderTransactionExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "localname": "ShareholderTransactionExpensesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_TotalAnnualExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Annual Expenses [Percent]" } } }, "localname": "TotalAnnualExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_UnderwritersCompensationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Underwriters Compensation [Percent]" } } }, "localname": "UnderwritersCompensationPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_WaiversAndReimbursementsOfFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "localname": "WaiversAndReimbursementsOfFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_WarrantsOrRightsCalledAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Amount" } } }, "localname": "WarrantsOrRightsCalledAmount", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_WarrantsOrRightsCalledPeriodDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Period [Date]" } } }, "localname": "WarrantsOrRightsCalledPeriodDate", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "cef_WarrantsOrRightsCalledTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Title" } } }, "localname": "WarrantsOrRightsCalledTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_WarrantsOrRightsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Exercise Price" } } }, "localname": "WarrantsOrRightsExercisePrice", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "dei_AdditionalSecurities462b": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "localname": "AdditionalSecurities462b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_AdditionalSecurities462bFileNumber": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "localname": "AdditionalSecurities462bFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_AdditionalSecuritiesEffective413b": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "localname": "AdditionalSecuritiesEffective413b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.", "label": "Approximate Date of Commencement of Proposed Sale to Public" } } }, "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateOrAsapItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r7", "r8" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_DelayedOrContinuousOffering": { "auth_ref": [ "r9", "r10", "r14" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "localname": "DelayedOrContinuousOffering", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DividendOrInterestReinvestmentPlanOnly": { "auth_ref": [ "r9", "r10", "r14" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "localname": "DividendOrInterestReinvestmentPlanOnly", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "submissionTypeItemType" }, "dei_EffectiveAfter60Days486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "localname": "EffectiveAfter60Days486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveOnDate486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "localname": "EffectiveOnDate486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "dei_EffectiveOnDate486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "localname": "EffectiveOnDate486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "dei_EffectiveOnSetDate486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "localname": "EffectiveOnSetDate486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveOnSetDate486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "localname": "EffectiveOnSetDate486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveUponFiling462e": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "localname": "EffectiveUponFiling462e", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveUponFiling486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "localname": "EffectiveUponFiling486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveWhenDeclaredSection8c": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "localname": "EffectiveWhenDeclaredSection8c", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInvCompanyType": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).", "label": "Entity Inv Company Type" } } }, "localname": "EntityInvCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "invCompanyType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "yesNoItemType" }, "dei_ExhibitsOnly462d": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "localname": "ExhibitsOnly462d", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_ExhibitsOnly462dFileNumber": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "localname": "ExhibitsOnly462dFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_InvestmentCompanyActFileNumber": { "auth_ref": [ "r10", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "localname": "InvestmentCompanyActFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_InvestmentCompanyActRegistration": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "localname": "InvestmentCompanyActRegistration", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_InvestmentCompanyRegistrationAmendment": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "localname": "InvestmentCompanyRegistrationAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "localname": "InvestmentCompanyRegistrationAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_NewEffectiveDateForPreviousFiling": { "auth_ref": [ "r10", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "localname": "NewEffectiveDateForPreviousFiling", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_NoSubstantiveChanges462c": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "localname": "NoSubstantiveChanges462c", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_NoSubstantiveChanges462cFileNumber": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "localname": "NoSubstantiveChanges462cFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_PostEffectiveAmendment": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "localname": "PostEffectiveAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_PostEffectiveAmendmentNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.", "label": "Post-Effective Amendment Number" } } }, "localname": "PostEffectiveAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreEffectiveAmendment": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "localname": "PreEffectiveAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_PreEffectiveAmendmentNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.", "label": "Pre-Effective Amendment Number" } } }, "localname": "PreEffectiveAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Form N-2", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form N-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form N-4", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form N-6", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form S-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Investment Company Act", "Number": "270", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "313", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "413", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r20": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r21": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r22": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r23": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "e", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r24": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "486", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r25": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "486", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r26": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r27": { "Name": "Securities Act", "Publisher": "SEC", "Section": "8", "Subsection": "c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Form F-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001558370-23-001226-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-001226-xbrl.zip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end